Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

12.1K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.1K
Amyloid Fibrils03:03

Amyloid Fibrils

6.8K
6.8K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Mutations01:39

Mutations

95.0K
Overview
95.0K
Mutations01:35

Mutations

44.8K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human microglial transitions at the Aβ-tau inflection point associate with divergent pathways to dementia and resilience.

Nature medicine·2026
Same author

Monocyte infiltration induces CNS arginine catabolism to fuel neuroinflammation.

Nature immunology·2026
Same author

Tracking the turning point in Alzheimer's disease.

Science (New York, N.Y.)·2026
Same author

Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC.

Research square·2026
Same author

Phagocytes as plaque catalysts: Human macrophages generate seeding-competent Aβ42 fibrils with cross-seeding activity.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Multiplexed spatial screening of lipid-based nanoparticles for extrahepatic messenger RNA targeting.

Journal of controlled release : official journal of the Controlled Release Society·2026

Related Experiment Video

Updated: Feb 25, 2026

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

621

Alzheimer's-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions.

Maria Szaruga1, Bogdan Munteanu2, Sam Lismont1

  • 1KU Leuven-VIB Center for Brain & Disease Research, VIB, 3000 Leuven, Belgium; Department of Neurosciences, Leuven Institute for Neuroscience and Disease, KU Leuven, 3000 Leuven, Belgium.

Cell
|July 29, 2017
PubMed
Summary

Alzheimer's disease mutations destabilize enzyme processing, leading to longer amyloid-beta peptides. Stabilizing these interactions may prevent Alzheimer's disease progression.

Keywords:
Alzheimer’s diseaseamyloid betaamyloid precursor proteinenzyme thermoactivitypresenilinprotein thermosabilityγ-secretase

More Related Videos

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

7.2K
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

12.4K

Related Experiment Videos

Last Updated: Feb 25, 2026

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

621
Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

7.2K
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

12.4K

Area of Science:

  • Molecular Biology
  • Neuroscience
  • Biochemistry

Background:

  • Alzheimer's disease (AD) is linked to mutations in Presenilins (PSEN) and amyloid precursor protein (APP).
  • These mutations alter amyloid-beta (Aβ) peptide length, a key factor in AD pathogenesis.
  • The precise mechanism driving this shift in Aβ length remains unclear.

Purpose of the Study:

  • To elucidate the mechanism by which PSEN and APP mutations influence Aβ peptide length.
  • To investigate the role of enzyme-substrate complex stability in γ-secretase processing.
  • To identify potential therapeutic targets for preventing AD.

Main Methods:

  • Investigated the stability of enzyme-substrate (E-S) complexes during sequential γ-secretase processing of APP.
  • Utilized pathogenic PSEN and APP mutations to assess their impact on E-S complex stability.
  • Examined the effects of environmental factors (temperature, compounds, detergent) and stabilizers on Aβ production and E-S complex stability.

Main Results:

  • Substrate shortening progressively destabilizes E-S complexes during APP processing by γ-secretase.
  • Pathogenic PSEN or APP mutations further destabilize these complexes, promoting longer Aβ peptide generation.
  • Destabilization of E-S complexes by various factors increases amyloidogenic Aβ release, while stabilizers enhance γ-secretase processivity.

Conclusions:

  • Presents a unifying model where PSEN/APP mutations and environmental factors destabilize E-S complexes, enhancing amyloidogenic Aβ production.
  • Suggests that environmental factors may contribute to AD risk.
  • Provides a theoretical foundation for developing γ-secretase/substrate stabilizing compounds to prevent AD.